In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin.
AUTOR(ES)
Tsuji, M
RESUMO
S-1090, a new oral cephalosporin, was active against selected gram-negative bacteria and methicillin-susceptible clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus warneri, against which it had excellent activity. S-1090 was the most active compound against Streptococcus pyogenes and Streptococcus agalactiae among the agents compared. The in vivo efficacy of S-1090 against systemic and urinary and respiratory tract infections caused by gram-positive and -negative bacteria was superior to that expected from the in vitro and in vivo activities of the agents against which it was compared.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=162981Documentos Relacionados
- In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.
- In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin.
- In vitro and in vivo antibacterial activities of BO-1341, a new antipseudomonal cephalosporin.
- In vitro antibacterial activity of ME1207, a new oral cephalosporin.
- In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin.
